Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics for $3.2 billion upfront. The ...
From GPT to Claude to Gemini, model names change fast, but use cases matter more. Here's how I choose the best model for the task at hand.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback